title: Management of metastatic hormone-sensitive prostate cancer.
abstract: In 2014, prostate cancer will affect roughly 15 % of American men during their lifetimes with about 230,000 new cases and 29,000 deaths per year. If required, most can be treated with curative surgery or radiotherapy. Upon relapse, androgen deprivation therapy (intermittent or continuous) is the cornerstone of treatment for hormone-sensitive disease. Response is variable and treatment is associated with a significant risk of toxicity. Recently, significant advances in survival have been demonstrated with chemohormonal therapy in men with high-volume disease. In addition, new findings have informed the approach to preventing bone complications in patients on therapy for metastatic hormone-sensitive prostate cancer. Devising clinical prediction tools and biomarkers is needed to select patients most likely to benefit from certain therapies and allow for a personalized approach.
authors: Dana-Farber Cancer Institute, 450 Brookline Avenue, D1230, Boston, MA, 02215, USA, brandond_bernard@dfci.harvard.edu.
authors: Brandon
authors: B
authors: Bernard
authors: Christopher J
authors: CJ
authors: Sweeney
mesh_terms: D000726:Androgen Antagonists / Q000008:administration & dosage* / Q000009:adverse effects; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage*; D001859:Bone Neoplasms / Q000556:secondary; D004334:Drug Administration Schedule; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists / Q000037:antagonists & inhibitors; D006801:Humans; D008297:Male; D010024:Osteoporosis / Q000139:chemically induced; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000556:secondary
chemical_list: D000726:Androgen Antagonists; D018931:Antineoplastic Agents, Hormonal; D007987:Gonadotropin-Releasing Hormone